Clinical Trials

List clinical trials by disease

The results of your search are listed below. To view the details of a trial or study, click on the "see details >>" link. Or start a new search.

Searched for: Pancreatic Cancer. 4 results shown below.

Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) (apact)

[Complete title: A Phase 3, Multicenter, Open-label, Randomized Study of nab®-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma]
Principal Investigator: Gabriela Chiorean
Study Number: 20140859
Phase: III

Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma

[Complete title: Phase Ib Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance and Preliminary Antineoplastic Activity of Gemcitabine Administered in Combination with Continuous Intravenous Doses of PRI-724, a CBP/ B-Catenin Inhibitor, to Patients with Advanced or Metastatic Pancreatic Adenocarcinoma Eligible for Second-Line Therapy after Failing First-Line Therapy with FOLFIRINOX (or FOLFOX)]
Principal Investigator: Elena Chiorean
Study Number: 20141153
Phase: I

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer (HALO-109-202)

[Complete title: A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Combined with nab-Paclitaxel Plus Gemcitabine Compared With nab-Paclitaxel Plus Gemcitabine in Subjects with Stage IV Previously Untreated Pancreatic Cancer( WIRB HALO-109-202)]
Principal Investigator: Sunil Hingorani, MD, PhD
Study Number: 2687.00
Phase: II

Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (PILLAR)

[Complete title: A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute - Pancreas) Immunotherapy in Subjects with Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer]
Principal Investigator: Andrew Coveler, MD
Study Number: 8028
Phase: III

Search Options

Select a disease from the list below:
Limit results to studies enrolling:

OR

Search by Keyword, Investigator Name or Study ID#:
Limit results to studies enrolling:

OR

View all studies
Limit results to studies enrolling:

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials

Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect and treat cancer and other life-threatening diseases.